Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation

Thrombosis Research

Volumn 121, Issue 4, 2008, Pages 447-453

  Tveit, Arnljot ^a   Seljeflot, Ingebjørg ^b   Grundvold, Irene ^b   Abdelnoor, Michael ^b   Smith, Pal ^a   Arnesen, Harald ^b  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGITOXIN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; VERAPAMIL; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVERSION; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINUS RHYTHM; UNSPECIFIED SIDE EFFECT;

AGED; ATRIAL FIBRILLATION; BODY MASS INDEX; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 38649136223     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.06.014     Document Type: Article

References (29)

1. Gustafsson C., Blomback M., Britton M., Hamsten A., and Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 21 1 (1990) 47-51
2. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., and Lip G.Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107 25 (2003) 3141-3145
3. Mitusch R., Siemens H.J., Garbe M., Wagner T., Sheikhzadeh A., and Diederich K.W. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 75 2 (1996) 219-223
4. Mondillo S., Sabatini L., Agricola E., Ammaturo T., Guerrini F., Barbati R., et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 75 2-3 (2000) 227-232
5. Roldan V., Marin F., Marco P., Martinez J.G., Calatayud R., and Sogorb F. Hypofibrinolysis in atrial fibrillation. Am Heart J 136 6 (1998) 956-960
6. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlof B., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 5 (2005) 712-719
7. Wachtell K., Hornestam B., Lehto M., Slotwiner D.J., Gerdts E., Olsen M.H., et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 5 (2005) 705-711
8. Young J.B., Dunlap M.E., Pfeffer M.A., Probstfield J.L., Cohen-Solal A., Dietz R., et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 17 (2004) 2618-2626
9. Skurk T., Lee Y.M., and Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37 5 (2001) 1336-1340
10. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., and Vaughan D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87 6 (1993) 1969-1973
11. Derosa G., Cicero A.F., Ciccarelli L., and Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 25 7 (2003) 2006-2021
12. Sawathiparnich P., Murphey L.J., Kumar S., Vaughan D.E., and Brown N.J. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88 8 (2003) 3867-3873
13. Skurk T., Lee Y.M., Nicuta-Rolfs T.O., Haastert B., Wirth A., and Hauner H. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. Diabetes Obes Metab 6 1 (2004) 56-62
14. Koh K.K., Chung W.J., Ahn J.Y., Han S.H., Kang W.C., Seo Y.H., et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 177 1 (2004) 155-160
15. Sironi L., Calvio A.M., Arnaboldi L., Corsini A., Parolari A., de Gasparo M., et al. Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 37 3 (2001) 961-966
16. Tveit A., Grundvold I., Olufsen M., Seljeflot I., Abdelnoor M., Arnesen H., et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol (2006)
17. Tveit A., Seljeflot I., Grundvold I., Abdelnoor M., Smith P., and Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 99 11 (2007) 1544-1548
18. Lee E., Vaughan D.E., Parikh S.H., Grodzinsky A.J., Libby P., Lark M.W., et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 78 1 (1996) 44-49
19. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86 1 (2001) 324-333
20. Oh C.K., Ariue B., Alban R.F., Shaw B., and Cho S.H. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 294 5 (2002) 1155-1160
21. Xu J., Cui G., Esmailian F., Plunkett M., Marelli D., Ardehali A., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 3 (2004) 363-368
22. Kelly D., Cockerill G., Ng L.L., Thompson M., Khan S., Samani N.J., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28 6 (2007) 711-718
23. Alessi M.C., and Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26 10 (2006) 2200-2207
24. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., and Hennekens C.H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341 8854 (1993) 1165-1168
25. Marin F., Roldan V., Climent V.E., Ibanez A., Garcia A., Marco P., et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 90 10 (2004) 1162-1166
26. Li-Saw-Hee F.L., Blann A.D., Gurney D., and Lip G.Y. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 22 18 (2001) 1741-1747
27. Conway D.S., Buggins P., Hughes E., and Lip G.Y. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 94 4 (2004) 508-510
28. Rosei E.A., Rizzoni D., Muiesan M.L., Sleiman I., Salvetti M., Monteduro C., et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 23 2 (2005) 435-444
29. Koh K.K., Ahn J.Y., Han S.H., Kim D.S., Jin D.K., Kim H.S., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 42 5 (2003) 905-910